The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFRl (TNFRSFlA) or TNFR2 (TNFRSFlA) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has thereputic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.La presente invención se refiere a oligonucleótidos de 12-16 nucleobases de longitud, caracterizado porque comprende una secuencia de nucleobases contigua la cual consiste en la SEQ ID NO: 246 o un oligómero de 16 nucleobases de longitud, que comprende una secuencia de nucleobases contigua la cual consiste de la SEQ ID NO: 244: en donde las letras mayúsculas representan LNA； el sobreíndice "o" representa oxi LNA； el subíndice "s" representa un enlace de fosforotiato； letras minúsculas representan ADN mC representa 5-metilcitosina； y en donde el LNA es beta-D-oxi LNa.
